No connection

Search Results

ELMD

BULLISH
$26.39 Live
Electromed, Inc. · AMEX
Target $37.0 (+40.2%)
$17.73 52W Range $30.73
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 26, 2026
Market cap
$218.39M
P/E
25.62
ROE
20.2%
Profit margin
13.1%
Debt/Equity
0.0
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
ELMD exhibits exceptional financial health, anchored by a strong Piotroski F-Score of 8/9 and a debt-free balance sheet (Debt/Equity 0.00). While the Graham Number suggests a defensive value of $11.28, the stock's growth profile—highlighted by a very low PEG ratio of 0.35 and consistent earnings beats—justifies its current premium. With an intrinsic value of $30.39 and an analyst target of $37.00, the stock is well-positioned for further upside. The combination of high gross margins (78.23%) and strong ROE (20.20%) indicates a highly efficient business model.

Key Strengths

Exceptional financial health with a Piotroski F-Score of 8/9
Zero debt and high liquidity (Current Ratio 4.86)
Strong profitability with 78.23% gross margins and 20.20% ROE
Significant undervaluation relative to growth (PEG Ratio 0.35)
Consistent track record of earnings surprises (3/4 beats in last year)

Key Risks

Forward P/E (43.26) is significantly higher than current P/E (25.62), suggesting potential earnings deceleration
Low insider sentiment and lack of recent insider buying activity
Small market cap ($0.22B) may lead to higher price volatility
Technical trend score is currently bearish (0/100) despite recent price gains
Lack of dividend yield for income-seeking investors
AI Fair Value Estimate
Based on comprehensive analysis
$31.5
+19.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
68
Strong
Value
70
Future
88
Past
85
Health
98
Dividend
0
AI Verdict
Strong Growth/Health Play
Key drivers: Zero debt, High margins, Low PEG ratio, Strong Piotroski score
Confidence
90%
Value
70/100

P/E 25.62, PEG 0.35, Graham $11.28

Positives
  • PEG ratio of 0.35 is highly attractive
  • Trading below intrinsic value ($30.39) and analyst target ($37.00)
Watchpoints
  • Trades at a significant premium to Graham Number ($11.28)
  • Price/Book is relatively high at 4.81
Future
88/100

Revenue Growth 16.30%, Earnings Growth 45.50%

Positives
  • Strong YoY earnings growth of 45.50%
  • Consistent quarterly EPS beats
Watchpoints
  • Forward P/E expansion suggests a potential cooling of earnings growth
Past
85/100

5Y Change +166.6%, 1Y Change +14.3%

Positives
  • Impressive 5-year price change of +166.6%
  • Steady upward trajectory in earnings over the last 4 quarters
Watchpoints
  • Historical volatility in earnings surprises (e.g., 2023-11 drop)
Health
98/100

Piotroski 8/9, Debt/Equity 0.00

Positives
  • Piotroski F-Score 8/9
  • Debt/Equity 0.00
  • Current Ratio 4.86
Watchpoints
  • Altman Z-Score not provided
Dividend
0/100

Yield N/A, Payout 0.00%

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0% payout ratio

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$26.39
Analyst Target
$37.0
Upside/Downside
+40.2%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ELMD and closest competitors.

Updated 2026-04-24
ELM
Electromed, Inc.
Primary
5Y
+166.6%
3Y
+151.3%
1Y
+14.3%
6M
+8.7%
1M
+7.0%
1W
+1.3%
LUC
Lucid Diagnostics Inc.
Peer
5Y
-89.1%
3Y
-5.9%
1Y
+7.6%
6M
+8.5%
1M
-6.6%
1W
+13.3%
CVR
CVRx, Inc.
Peer
5Y
-70.1%
3Y
-7.4%
1Y
-27.5%
6M
-4.1%
1M
+6.5%
1W
-11.5%
MGN
MacroGenics, Inc.
Peer
5Y
-88.9%
3Y
-46.5%
1Y
+173.2%
6M
+111.6%
1M
+15.7%
1W
+9.1%
SGH
Sight Sciences, Inc.
Peer
5Y
-87.8%
3Y
-52.7%
1Y
+53.8%
6M
-12.8%
1M
+10.8%
1W
+18.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
25.62
Forward P/E
43.26
PEG Ratio
0.35
P/B Ratio
4.81
P/S Ratio
3.17
EV/Revenue
2.97
EV/EBITDA
15.89
Market Cap
$218.39M

Profitability

Profit margins and return metrics

Profit Margin 13.06%
Operating Margin 19.16%
Gross Margin 78.23%
ROE 20.2%
ROA 13.62%

Growth

Revenue and earnings growth rates

Revenue Growth +16.3%
Earnings Growth +45.5%
Q/Q Revenue Growth +16.25%
Q/Q Earnings Growth +40.3%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.0
Low debt
Current Ratio
4.86
Strong
Quick Ratio
4.39
Excellent
Cash/Share
$1.67

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
78.4%
Op. Margin
19.2%
Net Margin
14.6%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.21x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
78%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-12
$N/A
2026-02-10
$0.32
+23.1% surprise
2025-11-12
$0.25
+21.9% surprise
2025-08-26
$0.25
+16.3% surprise

Healthcare Sector Comparison

Comparing ELMD against 548 companies in the Healthcare sector (30 bullish, 163 neutral, 355 bearish)
P/E Ratio
25.62
This Stock
vs
77.48
Sector Avg
-66.9% (Discount)
Return on Equity (ROE)
20.2%
This Stock
vs
-89.9%
Sector Avg
-122.5% (Below Avg)
Profit Margin
13.06%
This Stock
vs
-16.4%
Sector Avg
-179.6% (Weaker)
Debt to Equity
0.0
This Stock
vs
2.71
Sector Avg
-99.9% (Less Debt)
Revenue Growth
16.3%
This Stock
vs
126.74%
Sector Avg
-87.1% (Slower)
Current Ratio
4.86
This Stock
vs
4.53
Sector Avg
+7.3% (Better)

Similar Companies

Peer comparison within the same industry

ELMD Electromed, Inc.
BULLISH
Mkt Cap
$218M
P/E
25.6
ROE
20.2%
Price
$26.39
LUCD Lucid Diagnostics Inc.
BEARISH
Mkt Cap
$218M
P/E
-
ROE
-710.6%
Price
$1.28
 Compare with ELMD
CVRX CVRx, Inc.
BEARISH
Mkt Cap
$220M
P/E
-
ROE
-96.6%
Price
$8.37
 Compare with ELMD
MGNX MacroGenics, Inc.
BEARISH
Mkt Cap
$221M
P/E
-
ROE
-86.9%
Price
$3.47
 Compare with ELMD
SGHT Sight Sciences, Inc.
BEARISH
Mkt Cap
$221M
P/E
-
ROE
-50.7%
Price
$4.09
 Compare with ELMD

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

SKARVAN KATHLEEN S
Director
Stock Award
2025-12-01
3,000 shares
FLUET GREGORY J
Director
Stock Award
2025-12-01
3,000 shares
TUNE KATHLEEN A
Director
Stock Award
2025-12-01
3,000 shares
ERICKSON STAN K
Director
Stock Award
2025-12-01
3,000 shares
WALSH ANDREA M
Director
Stock Award
2025-12-01
3,000 shares
GALATOWITSCH JOSEPH L
Director
Stock Award
2025-12-01
3,000 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
FORM 8-K
2026-02-10
10-Q
FORM 10-Q
2026-02-10

ELMD filed its Form 10-Q on February 10, 2026. While the filing includes a section for Risk Factors under Item 1A, no specific financial highlights or detailed risk disclosures were provided in the available text.

8-K
FORM 8-K
2025-12-18
8-K
FORM 8-K
2025-11-18
10-Q
FORM 10-Q
2025-11-12

ELMD filed its Form 10-Q on November 12, 2025. The available excerpt identifies the inclusion of Risk Factors under Item 1A, although specific financial highlights and detailed risk disclosures were not provided.

8-K
FORM 8-K
2025-11-12
DEF 14A
FORM DEF 14A
2025-09-30

ELMD filed a Definitive Proxy Statement on September 30, 2025, providing shareholders with necessary information to vote on corporate matters at an upcoming meeting.

8-K
FORM 8-K
2025-09-09
10-K
FORM 10-K
2025-08-26

ELMD filed its annual 10-K report on August 26, 2025. Due to the limited content provided in the excerpts, specific financial highlights and risk factors are not available for analysis.

8-K
FORM 8-K
2025-08-26
10-Q
FORM 10-Q
2025-05-13
8-K
FORM 8-K
2025-05-13
8-K
8-K DATED MARCH 6, 2025
2025-03-10
10-Q
FORM 10Q
2025-02-11
8-K
FORM 8K
2025-02-11
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
4 analysts
Freedom Broker
2026-02-12
Maintains
Buy Buy
Freedom Broker
2025-11-19
Maintains
Buy Buy
Roth Capital
2025-11-13
reit
Buy Buy

Past News Coverage

Recent headlines mentioning ELMD from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile